Oral small molecule GLP-1 receptor agonist
Danuglipron 80 mg oral twice daily
DANU_PO_80MG_BID
Related
- All doses pooled: Danuglipron tablet
- Danuglipron 200 mg oral twice daily
- Danuglipron 140 mg tablet twice daily
- Danuglipron 40 mg oral twice daily
- Danuglipron 120 mg oral twice daily
- Danuglipron 160 mg oral twice daily
- Danuglipron 2.5 mg tablet twice daily
- Danuglipron 10 mg tablet twice daily
- Danuglipron 3 mg tablet
- Danuglipron 10 mg tablet
- Danuglipron 30 mg tablet
- Danuglipron 100 mg tablet
- Danuglipron 300 mg tablet
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.72 (0.01 to 56.74) | 0.42 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.53 (0.36 to 33.46) | 0.37 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 6.41 (1.23 to 39.86) | 0.13 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.27 (0.16 to 9.14) | 0.42 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.81 (1.45 to 10.86) | 0.24 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 13.02 (4.77 to 44.36) | 0.06 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 18.71 (4.80 to 96.57) | 0.07 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 5.52 (1.84 to 20.10) | 0.11 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 6.50 (0.69 to 70.61) | 0.23 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 8.05 (0.26 to 260) | 0.18 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.87 (0.05 to 14.68) | 0.47 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.01 (0.19 to 26.21) | 0.37 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.98 (1.02 to 36.09) | 0.27 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.13 (0.99 to 12.08) | 0.55 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.96 (0.16 to 6.61) | 0.83 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.97 (0.68 to 16.79) | 0.34 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.92 (0.45 to 10.43) | 0.50 |
Trials
- NCT04707313A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06882961 ADMINISTRATION IN ADULTS WITH OBESITY2021 · 628 randomized · 26 weeks
- NCT03985293A 16-WEEK, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE2020 · 412 randomized · 16 weeks
- NCT04552470AN 8-WEEK PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TWICE DAILY PF-06882961 ADMINISTRATION IN JAPANESE ADULTS WITH TYPE 2 DIABETES MELLITUS2020 · 37 randomized · 8 weeks